Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00051259 · ClinicalTrials.gov registry record · Phase 3
Effects of Antidepressants on Sexual Functioning
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 420
- Enrollment target
NCT00051259 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 420 participants.
The verdict
NCT00051259, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 420 participants
- Enrollment target
Study Summary
The purpose of this trial is to study the effects of two depression medications on sexual functioning.
Interventions
- DRUG Extended-Release Bupropion Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2003-01 |
| Est. Completion | 2004-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00051259
The ClinicalTrials.gov registry entry for NCT00051259 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Extended-Release Bupropion Hydrochloride is the first listed.
NCT00051259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00051259 about?
NCT00051259 is a clinical study titled "Effects of Antidepressants on Sexual Functioning". The purpose of this trial is to study the effects of two depression medications on sexual functioning.
What is the current status of trial NCT00051259?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 420 participants. The study started on 2003-01. Estimated completion is 2004-06.
What interventions are being tested in trial NCT00051259?
The interventions under investigation include: Extended-Release Bupropion Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00051259?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.